

Original Article

Cite this article: Zope MK, Patil D, Raj R, Ansari S, Madhawi R, Kumar A, Devi S, Sinha D, Singh R, and Singh D. (2025) Analytical study of radiotherapy techniques in left-sided breast irradiation using integrated scoring and risk assessment method. *Journal of Radiotherapy in Practice*. 24(e26), 1–10. doi: [10.1017/S1460396925000081](https://doi.org/10.1017/S1460396925000081)

Received: 27 November 2024

Revised: 24 January 2025

Accepted: 4 February 2025

Keywords:

Correlation analysis; IMRT; integrated scoring; left-sided breast cancer; radiotherapy; risk assessment; VMAT

Corresponding author:

Deepali Patil; Email: mpdeepali23@gmail.com

We confirm that this work is original and has not been published elsewhere nor is it currently under consideration for publication elsewhere. We have no conflicts of interest to disclose. All authors approved the manuscript and its submission to the journal. Thank you for your consideration of this manuscript.

© The Author(s), 2025. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and/or adaptation of the article.



Analytical study of radiotherapy techniques in left-sided breast irradiation using integrated scoring and risk assessment method

Mukesh Kumar Zope¹ , Deepali Patil¹ , Rishi Raj² , Shahanawaj Ansari³ , Richa Madhawi⁴ , Abhishek Kumar⁴ , Seema Devi⁴ , Dinesh Sinha⁴ , Rajesh Singh⁴ and Devraj Singh⁵

¹Department of Medical Physics, State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, BR, India;

²School of Computer Engineering Kalinga Institute of Industrial Technology, Bhubaneswar, OD, India; ³Apollo Hospitals Bilaspur, Bilaspur, CG, India; ⁴Department of Radiation Oncology, State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, BR, India and ⁵Institute of Physical Sciences for Study & Research, Veer Bahadur Singh Purvanchal University, Jaunpur, UP, India

Abstract

Background: Optimal radiotherapy technique selection for left-sided breast cancer remains challenging. This study compared volumetric-modulated arc therapy (VMAT), VMAT+IMRT (VMAT+IMRT) and IMRT+VMAT (IMRT+VMAT) using an innovative integrated scoring system and risk factor (RF) assessment.

Methods: Retrospectively analysed 41 patients with left-sided breast cancer. Treatment plans were evaluated using an integrated scoring system considering tumour coverage and organs at risk (OARs) sparing. RF analysis assessed potential adverse effects on the heart and lungs. Correlation analysis explored relationships between integrated scores and risk factors.

Results: VMAT showed the best overall integrated score (1.0931 ± 0.1707), followed by IMRT+VMAT (1.2011 ± 0.2440) and VMAT+IMRT (1.2264 ± 0.2499). VMAT had the highest percentage of Excellent OAR plans (14.6%), while VMAT+IMRT and IMRT+VMAT showed better PTV coverage (53.7% and 51.2% Excellent, respectively). RF analysis revealed: VMAT (heart RF: 0.341, lung RF: 0.671), VMAT+IMRT (heart RF: 0.294, lung RF: 0.750) and IMRT+VMAT (heart RF: 0.533, lung RF: 0.546). Correlation analysis showed strong positive correlations between integrated scores and lung RF for VMAT ($r = 0.671$) and VMAT+IMRT ($r = 0.750$), with IMRT+VMAT showing moderate correlations for lung ($r = 0.546$) and heart ($r = 0.533$) RFs.

Conclusion: VMAT demonstrated the best balance between PTV coverage and OAR sparing, hybrid techniques improved target coverage but increased risk to OAR. The RF analysis highlighted varying impacts on heart and lung across techniques. This analysis provides valuable insights for technique selection, potentially improving treatment outcomes and reducing complications in left-sided breast cancer radiotherapy.

Introduction

Breast cancer continues to pose a considerable challenge to global health, as evidenced by GLOBOCAN 2022 data, which ranks it as the most commonly diagnosed cancer among women, representing 11.6% of all cancer cases and 6.9% of cancer-related fatalities worldwide.¹ Post-mastectomy radiation therapy (PMRT) has been shown to effectively decrease rates of locoregional recurrence and enhance overall survival among breast cancer patients.² Nevertheless, the intricacies of PMRT, especially in cases of left-sided breast cancer, involve the challenge of accurately targeting the treatment area while minimising radiation exposure to vital organs at risk (OAR), including the heart and lungs.^{3,4}

Advanced radiation techniques, such as intensity-modulated radiation therapy (IMRT) and VMAT, have shown effectiveness in enhancing dose conformity and reducing cardiac exposure for patients with left-sided breast cancer.^{5,6} However, the use of these advanced techniques may result in a larger volume of healthy tissue receiving low-dose radiation, thereby potentially increasing the likelihood of secondary malignancies.^{7,8}

Recent studies have explored the integration of IMRT and VMAT through hybrid techniques, aiming to combine the precision of IMRT with the efficiency of VMAT.^{8,9} Despite these advancements, the challenge of selecting the optimal technique for individual patients continues, as varying dosimetric indices may favour different approaches.^{10,11}

The plan evaluation process requires an analysis of dosimetric indices for planning target volumes (PTVs), an assessment of dose–volume criteria for OARs and a review of treatment



parameters along with clinical factors. Various methods have been developed to support the evaluation of treatment plans, aiming to quantify and compare the quality of different radiotherapy plans.

These approaches are typically classified into two primary categories: unified dosimetric index (UDI) methodologies and scoring systems. UDI methods, as defined by Akpati *et al.*¹² and Mambretti *et al.*,¹³ consolidate multiple dosimetric parameters into a single metric, enabling a comprehensive evaluation of treatment plans. Scoring systems, as discussed in the studies,^{14–17} offer an in-depth analysis of plan quality across various parameters, often allowing for more personalised assessments.

Building on these concepts, Leung *et al.*¹⁴ presented an innovative dose–volume-based Plan Quality Index aimed at facilitating the comparison of IMRT plans. Ruan *et al.*¹⁵ illustrated the progression of treatment plan quality criteria derived from the specific experiences of various institutions. Song *et al.*¹⁶ suggested the implementation of patient-specific dosimetric endpoints to enhance quality control in radiotherapy treatment planning. Additionally, Alfonso *et al.*¹⁷ created a decision-support system based on dose–volume histograms (DVH) to assist in the dosimetric comparison of radiotherapy treatment plans. Balaji *et al.*¹⁸ introduced an extensive scoring formula that combines dosimetric indices for PTVs and OARs, incorporating designated penalties and applying a consistent weighting factor of one across all dosimetric indices. In addition to these dosimetric evaluation methods, Ansari *et al.*¹⁹ presented a novel approach for evaluating risk factors (RFs) associated with OAR, which considers radiobiological elements.

The aim of this research is to thoroughly assess and compare advanced radiotherapy methods for treating left-sided breast cancer, with a particular emphasis on Five Partial Arc (5P)-VMAT, VMAT in conjunction with IMRT (VMAT+IMRT) and IMRT in conjunction with VMAT (IMRT+VMAT). By utilising the innovative scoring formula introduced by Balaji *et al.*¹⁸ alongside the risk-assessment strategies suggested by Ansari *et al.*,¹⁹ we seek to create a robust evaluation framework tailored to individual patients. This innovative methodology not only improves the optimisation of treatment plans but also has the potential to enhance patient outcomes by offering a more detailed and comprehensive approach to selecting radiotherapy techniques. To our knowledge, this study represents the first systematic exploration that integrates these advanced evaluation methods in radiotherapy, signifying a notable advancement in personalised cancer treatment approaches.

Methods and Materials

Patient's selection, characteristics and simulation

A retrospective analysis was conducted involving 41 female patients diagnosed with left-sided breast cancer who underwent VMAT radiotherapy at the State Cancer Institute, Indira Gandhi Institute of Medical Science, Patna, between December 2022 and June 2024. The criteria for inclusion required patients to be at least 18 years of age, possess histologically confirmed left-sided breast cancer and have complete medical records pertaining to their VMAT treatment. Exclusion criteria encompassed male patients, those with right-sided breast cancer, metastatic disease, incomplete medical documentation or treatment and individuals who were pregnant. The median age of the participants was 47 years, with an age range of 29 to 76 years, and tumor stages ranging from T1 to T4, along with nodal involvement classified as N0 to N3 (either

N2b or N3b were not present) following modified radical mastectomy. Patients received neoadjuvant or adjuvant chemotherapy according to stage hormone receptor and HER-2 status.

CT simulation was performed using a Revolution EVO (GE healthcare) CT simulator with a slice thickness of 2.5 mm. Patients were positioned supine on an all-in-one base plate breast board, secured with a two-clamp thermoplastic mask. The affected arm was elevated to at least 90 degrees, and the head was rotated to the opposite side. The CT images were subsequently imported into the eclipse treatment planning system (Varian Medical Systems, Palo Alto, USA), where the clinical target volume, PTV and OARs, including the heart and lungs, were delineated in accordance with RTOG guidelines.²⁰ The study received approval from the institutional review board.

Target dose and treatment planning

The Eclipse treatment planning system (version 16.1, Varian Medical Systems, USA) was utilised to create and refine treatment plans, which were delivered on a Varian TrueBeam SVC linear accelerator featuring Millennium 120 multileaf collimators (MLC). Three different planning methodologies were employed: VMAT, VMAT+IMRT and IMRT+VMAT with a 6MV photon beam. The cumulative prescribed dose to the PTV was 40.05 Gy in 15 fractions, with each fraction delivering 2.67 Gy over duration of 3 weeks. Two hybrid strategies were developed: IMRT+VMAT and VMAT+IMRT. In all these hybrid plans, the prescribed dose was allocated between the IMRT (70%, 1.9 Gy) and VMAT (30%, 0.8 Gy) components. For the IMRT+VMAT approach, the IMRT component employed four beam angles (300°, 315°, 120° and 135°) with collimation angles set at 30° and 330°. The VMAT component included two partial arcs: one spanning from 305° to 50° in a clockwise direction and the other from 160° to 60° in counter-clockwise direction, both maintaining a collimation angle of ±30°. In the VMAT+IMRT configuration, the dose distribution was inverted, with VMAT delivering 1.9 Gy and IMRT providing 0.8 Gy, while retaining the same beam arrangement for the IMRT component. Furthermore, a five-partial arc VMAT plan was created, which included jaw splitting and the following arc configurations: 310°–41° (collimator 17°), 81°–160° (343°), 331°–160° (80°), 160°–81° (357°) and 41°–310° (3°). This beam arrangement, as detailed in Patil *et al.*,²¹ has demonstrated effectiveness in enhancing dose delivery while reducing exposure to critical organs in my previous studies. All VMAT plans underwent optimisation using the photon optimiser (PO), and final dose calculations were conducted with the anisotropic analytical algorithm (AAA), utilising a grid of 2.5 mm. The optimisation process for the hybrid plans involved establishing a base plan, optimising the second component with reference to the base plan, integrating the components and normalising to 100% of the target mean dose. Consistent optimisation constraints were applied across all plans, with adjustments made to PTV's priority, weights as necessary to ensure sufficient coverage.

Plan evaluation method

A DVH analysis was performed to assess the dosimetric characteristics of PTVs and OARs across all treatment plans. Essential dosimetric metrics for PTVs, such as the coverage index (COI), uniformity index (UI), conformity index (CI) and gradient index (GI), were utilised alongside dose–volume parameters for OARs, as detailed in Table 1, for comparative evaluation. Furthermore, monitor units (MU) were analysed to determine the efficiency of the treatment delivery process.

Table 1. Dosimetric parameters and organ at risks constraints for left-sided breast cancer

Parameter	Formula	Description	Ideal Value (Desirable Value)
PTV			
Gradient Index (GI)	$GI = V_{50\%}/V_{PTV}$	V50% is the volume of the 50% isodose line, VPTV is the volume of the planning target volume (PTV).	1 (≤ 3.5)
Conformity Index (CI)	$CI = V_{ref}/V_{PTV}$	Vref is the volume of the reference isodose (usually 95% of the prescription dose).	1 (1)
Homogeneity Index (HI)	$HI = D_{max}/PD$	Dmax is the maximum dose within the PTV.	1 (≤ 1.15)
Coverage Index (COI)	$COI = D_p/D_{95\%}$	Dp is the prescription dose, and D95% is the dose received by 95% of the PTV.	1 (≤ 1.05)
Uniformity Index (UI)	$UI = D_{2\%}/D_{98\%}$	D2% and D98% are the doses received by 2% and 98% of the PTV, respectively.	1 (≤ 1.15)
PTV Coverage	$Coverage = D_{min}/PD$	Dmin is the minimum dose within the PTV, and PD is the prescribed dose.	≥ 0.9 (≥ 0.8)
Body D2cc		Maximum dose to 2 cc of the body outside the PTV.	$<107\%$
OARs			
Left Lung	$D_{mean} < 12\text{Gy}(13\text{Gy})$	Heart	$D_{mean} < 5\text{Gy}$
	$V5\text{Gy} < 60\% (65\%)$		$V5\text{Gy} < 40\%$
	$V10\text{Gy} < 40\%$		$V25\text{Gy} < 10\%$
	$V20\text{Gy} < 25\% (30\%)$		$V35\text{Gy} < 5\%$
	$V35\text{Gy} < 10\%$		
Right Lung	$D_{mean} < 2\text{Gy}$	Contralateral (C/L) Breast	$D_{mean} < 3.5\text{Gy}$
Oesophagus	$D_{mean} < 10\text{Gy}$	Thyroid/ Spinal Cord	$D10\% < 35\text{Gy} / D_{max} < 45\text{Gy}$

VxGy: volume of an organ receiving a dose of x Gray (Gy); Dmean represents the mean dose; Dmax represents the maximum dose; D10% represents the dose received by 10% of the volume.

Integrating scoring method

An integrated scoring approach, akin to that utilised by Balaji et al.¹⁸ was employed to amalgamate all dosimetric indices pertaining to the PTVs, OARs and delivery parameters such as MU and TT into a unified score. The calculation of the integrated score was as follows:

$$\text{Integrated score} = \frac{\sum_{i=1}^n \text{Individual score}_i}{n}$$

$$\text{Individual score}_i = \left(\frac{A_i}{D_i} \right) \times P_i \times W_i$$

In this context, A_i represents the achieved value of the i^{th} dosimetric index, while D_i denotes the desired value, and n indicates the total number of indices evaluated. The penalty function P_i serves to double the score for results that are deemed unacceptable or exhibit statistically significant differences between treatment plans. The weighting factor W_i , which ranges from 0.1 to 1, enables clinicians to modify the importance of each index according to specific clinical requirements. For instance, in elderly patients, a reduced weighting factor may be applied to high-dose parameters (such as V35Gy) to mitigate toxicity risks to the lung and heart. In contrast, for younger patients (those under 45 years of age), a lower weighting factor might be assigned to low-dose

parameters (like V5Gy) to decrease the likelihood of secondary cancer development.

Risk assessment method

The risk factor (RF) assessment methodology developed by Ansari et al.¹⁹ examines the potential toxicity to healthy organs adjacent to the target volume during irradiation, taking into account the organ's tolerance dose (TD). The likelihood of injury to an organ at risk (OAR) is influenced by its total volume (V_{TO}), the specific type of organ and the degree of its irradiated subvolumes. The formula used to compute the RF is as follows:

$$RF = D_P \times \{(V_{VOI})/(V_{TO} \times D_{TDO})\}$$

In this context, D_P represents the prescribed dose to the planning target volume (PTV), V_{VOI} denotes the volume of the organ that has been irradiated (calculated as the total organ volume minus the volume corresponding to the reference isodose), V_{TO} refers to the total volume of the organ and D_{TDO} indicates the tolerance dose of the organ. This approach aids in assessing the potential risk of toxicity by considering the volume effect of the organ during the irradiation process.

Definition of performance thresholds

In order to assess the quality of treatment plans, performance thresholds for PTV coverage and OAR sparing were determined




Figure 1. This illustration presents three transverse CT slices that depict the dose distribution of three distinct radiotherapy treatment plans: VMAT, VMAT+IMRT and IMRT+VMAT. The isodose lines extend from the highest dose percentage to a minimum of 20%.




Figure 2. Illustrates a dose-volume histogram (DVH) comparing three different radiotherapy treatment techniques: VMAT, VMAT+IMRT and IMRT+VMAT.

through a statistical distribution-based methodology. For each planning technique (VMAT, V+I and I+V), the mean (μ) and standard deviation (σ) of dosimetric metrics were computed. The thresholds were classified into four performance categories: Excellent (below $\mu - \sigma$), Good (from $\mu - \sigma$ to μ), Average (from μ to $\mu + \sigma$) and Poor (above $\mu + \sigma$). This approach facilitated an objective and uniform evaluation of plan quality across all techniques.

Integral dose (ID)

The integral dose represents the total energy absorbed by an organ. To calculate the ID, the mean organ dose, mean organ density and mean organ volume are utilised, as defined by the formula:

$$ID = D_{\text{mean}} * V_{\text{mean}} * \rho_{\text{mean}} \text{ (Gy-L)}^{22,23}$$

In this equation, D_{mean} signifies the mean organ dose, V_{mean} denotes the organ volume and ρ_{mean} indicates the mean organ

density. In this study, all organs are assumed to have a uniform density ($\rho = 1$); thus, the ID is computed using the following formula:

$$ID = D_{\text{mean}} * V_{\text{mean}} \text{ (Gy-L)}^{22,23}$$

Results

This study evaluated three distinct treatment planning method including VMAT, VMAT+IMRT and IMRT+VMAT in relation to dosimetric parameters associated with the planning target volume (PTV) and OARs, utilising individual scoring methods as outlined by Balaji et al.¹⁸ and RF assessment methods as outlined by Ansari et al.¹⁹

Figure 1 presents a comparative analysis of the three treatment planning techniques. In Figure 1, the colour wash isodose distribution patterns are shown, ranging from maximum to 20%, across the three planning methods (VMAT, VMAT+IMRT and IMRT+VMAT) utilised for the treatment of left-sided breast

Table 2. The mean achieved value and individual score results for all dosimetric indices related to PTV and organs at risks

Parameters	Mean Achieved Value (Individual Score)		
	VMAT	VMAT+IMRT	IMRT+VMAT
PTV			
Gradient Index (GI)	2.95 (0.94)	3.13 (1.22)	3.19 (1.21)
Conformity Index (CI)	0.98 (0.98)	0.97 (0.97)	0.975 (0.97)
Homogeneity Index (HI)	1.08 (0.94)	1.09 (0.95)	1.09 (0.94)
Coverage Index (COI)	1.04 (1.09)	1.04 (1.02)	1.04 (1.02)
Uniformity Index (UI)	1.09 (0.95)	1.08 (0.94)	1.10 (0.98)
Coverage	0.78 (0.98)	0.73 (0.91)	0.70 (0.88)
BODY D2cc	105.44 (1.03)	105.88 (1.14)	105.33 (1.01)
MU	1033.96	1009.43	1118.73
OARs			
Left Lung			
Dmean	12.69 (1.44)	13.62 (1.89)	13.54 (1.89)
V5Gy	59.81 (0.7)	59.63 (0.77)	56.69 (0.67)
V10Gy	40.09 (1.61)	42.31 (1.98)	41.74 (1.86)
V20Gy	24.90 (0.86)	28.22 (1.42)	28.85 (1.52)
V35Gy	10.59 (1.01)	13.46 (1.75)	14.57 (2.02)
Heart			
Dmean	5.14 (1.92)	6.25 (3.12)	6.38 (3.29)
V5Gy	22.16 (1.01)	29.04 (0.56)	29.92 (0.54)
V25Gy	4.50 (0.48)	6.51 (0.82)	9.01 (1.4)
V35Gy	1.51 (0.13)	2.55 (0.28)	3.06 (0.44)
Right Lung			
Dmean	1.96 (1.67)	1.68 (1.19)	1.01 (0.5)
Contralateral Breast			
Dmean	2.89 (1.17)	2.59 (1.16)	1.89 (0.61)
Oesophagus			
Dmean	9.11 (1.45)	8.57 (1.3)	7.21 (0.86)
Thyroid			
D10%	39.9 (2.6)	40 (2.62)	40 (2.62)
Spinal Cord			
Dmax	18.8 (0.42)	13.1 (0.29)	9.01 (0.2)

VxGy: volume of an organ receiving a dose of x Gray (Gy); Dmean represents the mean dose; Dmax represents the maximum dose; D10% represents the dose received by 10% of the volume.

cancer. Figure 2 illustrates the associated DVH for the three techniques, offering a quantitative assessment of dose distribution within target volumes and critical structures.

Table 2. The mean achieved value and individual score results for all dosimetric indices related to PTV and organs at risks.

Planning target volume with individual score

The Gradient Index (GI) recorded the lowest value for the VMAT technique at 2.95, with the VMAT+IMRT technique at 3.13 and the IMRT+VMAT technique at 3.19. In terms of individual score

performance, the VMAT technique excelled with a score of 0.94, while the VMAT+IMRT and IMRT+VMAT techniques yielded comparable scores of 1.22 and 1.21, respectively. The CI exhibited minor variations among the techniques, with VMAT achieving a slightly superior conformity score of 0.98 and an individual score of 0.98, in contrast to VMAT+IMRT at 0.97 and IMRT+VMAT at 0.97 both of which had individual scores of 0.97. Both the homogeneity index (HI) and COI remained stable across all techniques. The HI values ranged from 1.08 to 1.09, while the COI was recorded at 1.04. In terms of individual COI scores, VMAT+IMRT and IMRT+VMAT (1.02) outperformed VMAT (1.09).

Table 3. Integrated scores analysis for VMAT, VMAT+IMRT, and IMRT+VMAT planning Metrics including PTV and OARs

Planning Metric	VMAT		VMAT+IMRT		IMRT+VMAT	
Key Statistics	PTV	OARs	PTV	OARs	PTV	OARs
Mean (μ)	0.987	1.1228	1.019	1.3663	1.009	1.3125
Std. Dev (σ)	0.0768	0.2645	0.1019	0.3978	0.1037	0.3842
Best Score	1.2443	0.6950	1.3203	0.7927	1.2822	0.7098
Worst Score	0.9419	1.7758	0.9545	2.3170	0.9640	2.2587
Integrated Score	1.06 ± 0.1707		1.19 ± 0.2499		1.16 ± 0.2440	
Categorisation						
Excellent	18(43.9%)	6(14.6%)	22(53.7%)	6(14.6%)	21(51.2%)	6(14.6%)
Good	20(48.8%)	20(48.8%)	12(29.3%)	17(41.5%)	12(29.3%)	18(43.9%)
Average	3(73%)	9(22%)	6(14.6%)	11(26.8%)	8(19.5%)	10(24.4%)
Poor	0(0%)	6(14.6%)	1(2.4%)	7(17.1%)	0(0%)	7(17.1%)
Thresholds						
Excellent	<1.0473	<0.8583	<1.3561	<0.9685	<1.2819	<0.9283
Good	1.0473 – 1.2173	0.8583 – 1.1228	1.3561 – 1.5601	0.9685 – 1.3663	1.2819 – 1.4893	0.9283 – 1.3125
Average	1.2173 – 1.3873	1.1228 – 1.3873	1.5601 – 1.7641	1.3663 – 1.7641	1.4893 – 1.6967	1.3125 – 1.6967
Poor	>1.3873	>1.3873	>1.7641	>1.7641	>1.6967	>1.6967

The Uniformity Index (UI) varied between 1.08 and 1.10, with VMAT+IMRT demonstrating the uniformity is 1.08 (individual score of 0.94), followed by VMAT (0.95) and IMRT+VMAT (0.98). PTV coverage was greatest for the VMAT technique at 0.78, followed by VMAT+IMRT at 0.73 and IMRT+VMAT at 0.70. Regarding BODY D2cc, the IMRT+VMAT technique achieved the highest individual score of 1.01, closely trailed by VMAT at 1.03, while VMAT+IMRT recorded a slightly elevated score of 1.14.

Organs at risk with individual score

Left Lung: The VMAT+IMRT and IMRT+VMAT techniques yielded higher average doses, recording individual scores of 13.62 Gy (1.89) and 13.54 Gy (1.89), respectively, in contrast to the VMAT technique, which had a mean dose of 12.69 Gy and an individual score of 1.44. Regarding V5Gy, the IMRT+VMAT technique demonstrated the smallest volume at 56.67%, accompanied by an integrated score of 0.67. This was followed by the VMAT technique at 59.81% (individual score: 0.70) and the VMAT+IMRT technique at 59.63% (individual score: 0.77). For V10Gy, the VMAT technique recorded the lowest percentage at 40.09%, with an individual score of 1.61. The IMRT+VMAT technique followed at 41.74% (1.86), and the VMAT+IMRT technique was at 42.31% (1.98). In the case of V20Gy, the VMAT technique again had the lowest value at 24.90%, with an individual score of 0.86. This was succeeded by the VMAT+IMRT technique at 28.22% (1.42) and the IMRT+VMAT technique at 28.85% (1.52). Lastly, for V35Gy, the VMAT technique exhibited the lowest volume at 10.59%, with an individual score of 1.01, followed by the VMAT+IMRT technique at 13.46% (1.75) and the IMRT+VMAT technique at 14.57% (2.02).

Heart: The VMAT technique recorded the lowest average dose, measuring 5.14 Gy (1.92), while both the VMAT+IMRT and IMRT+VMAT techniques exhibited comparable average doses of

6.25 Gy, each with an individual score of 3.29. In terms of V5Gy, the VMAT technique demonstrated the smallest volume at 22.16%, achieving an individual score of 1.01. This was followed closely by the VMAT+IMRT and IMRT+VMAT techniques, which both had volumes of 29.92% and individual scores of 0.56. For V25Gy, the VMAT technique again had the lowest percentage at 4.50%, with an individual score of 0.48. The VMAT+IMRT technique followed with a value of 6.51% (0.82), while the IMRT+VMAT technique recorded 9.01% (1.40). Regarding V35Gy, the VMAT technique maintained the lowest percentage at 1.51%, resulting in an individual score of 0.13. In contrast, the VMAT+IMRT and IMRT+VMAT techniques were at 3.06%, each with an individual score of 0.44.

Right Lung and Contralateral Breast: The VMAT technique demonstrated greater average doses for the right lung, achieving an individual score of 1.96 Gy (1.67), in contrast to VMAT+IMRT, which recorded 1.68 Gy (1.19), and IMRT+VMAT, which had a score of 1.01 Gy (0.5). A comparable pattern was noted for the contralateral breast, where the VMAT technique again led with a score of 1.17, followed closely by VMAT+IMRT at 1.16 and IMRT+VMAT at 0.61.

Oesophagus, Thyroid and Spinal Cord: For the oesophagus, the average dose recorded was the highest for the VMAT technique at 9.11 Gy (1.45), followed by the VMAT+IMRT technique at 8.57 Gy (1.30) and the IMRT+VMAT technique at 7.21 Gy (0.86). In terms of the thyroid, the D10% values remained consistent across all techniques, with individual measurements falling between 39.9 and 40 Gy (2.60–2.62). Regarding the spinal cord, the maximum dose was also highest for the VMAT technique at 18.8 Gy (0.42), followed by the VMAT+IMRT technique at 13.1 Gy (0.29) and the IMRT+VMAT technique at 9.01 Gy (0.20).


Table 3 presents a comprehensive analysis of integrated scores for VMAT, VMAT+IMRT and IMRT+VMAT metrics, comparing OARs and PTV performance. The average scores for OARs were consistently elevated across all evaluated techniques (VMAT:

Table 4. Risk factor (RF) analysis and correlation between integrated score and RF in three different techniques

OARs	Tolerance Dose (Mean Dose)	Endpoint	Risk Factor			Correlation Coefficient between (Integrated Score Vs. Risk Factor)		
			V	VMAT+IMRT	IMRT+VMAT	V	VMAT+IMRT	IMRT+VMAT
Heart	26 Gy	Pericarditis	0.06 ± 0.040	0.09 ± 0.050	0.10 ± 0.591	0.34	0.29	0.53
Lung	20 Gy	Radiation pneumonitis	0.49 ± 0.072	0.56 ± 0.091	0.57 ± 0.095	0.67	0.75	0.55

Table 5. Integral dose across three techniques including PTV and OARs

Integral Dose	VMAT	VMAT+IMRT	IMRT+VMAT	V vs VMAT+IMRT	V vs IMRT+VMAT	VMAT+IMRT vs IMRT+VMAT
	Mean ± SD	Mean ± SD	Mean ± SD	P-value	P-value	P-value
PTV	25831.53 ± 7716	25776.67 ± 7714	25782.38 ± 7714	0.002	<0.001	0.563
OARs	4652.21 ± 4538	4868.49 ± 4979	4557.68 ± 5087	0.001	0.229	<0.001
Left Lung	11852.05 ± 3185	12716.73 ± 3462	12629.24 ± 3316	<0.001	<0.001	0.282
Heart	2663.5 ± 996	3252.58 ± 1177	3315.46 ± 1236	<0.001	<0.001	0.224
Right Lung	2188.68 ± 958	1886.86 ± 1073	1140.58 ± 627	0.006	<0.001	<0.001
C/L Breast	1904.61 ± 850	1617.77 ± 874	1145.44 ± 508	0.014	<0.001	<0.001

**Figure 3.** Correlation coefficients between individual and integrated scores in the PTV dosimetric parameters.

1.1228, VMAT+IMRT: 1.3663 and IMRT+VMAT: 1.3125) in comparison to the scores for PTV (VMAT: 1.0633, VMAT+IMRT: 1.0865 and IMRT+VMAT: 1.0897). Furthermore, the standard deviations for the OARs metrics were significantly higher (VMAT: 0.2645, VMAT+IMRT: 0.3978 and IMRT+VMAT: 0.3842) than those observed for the PTV metrics (VMAT: 0.0768, VMAT+IMRT: 0.1019 and IMRT+VMAT: 0.1037), suggesting a greater degree of variability in the performance of OARs. The classification of scores indicates clear distinctions between OARs and PTV. For OARs, a significant majority of scores were classified as Good across all evaluated metrics (VMAT: 48.8%, VMAT+IMRT: 41.5% and IMRT+VMAT: 43.9%), while a steady 14.6% were rated as Excellent. Conversely, PTV scores exhibited a greater representation in the Excellent category (VMAT: 43.9%, VMAT+IMRT: 53.7%, IMRT+VMAT: 51.2%), with a reduced number of scores falling into the Average and Poor categories. It is important to highlight that, although the percentage of Poor scores for OARs

remained relatively stable across various metrics (ranging from 14.6% to 17.1%), the PTV scores infrequently categorised as Poor, with only the VMAT+IMRT metric exhibiting a 24% Poor score. The threshold analysis demonstrated that VMAT consistently attained lower (more advantageous) threshold values across all categories in comparison to VMAT+IMRT and IMRT+VMAT. For example, the threshold for “Excellent” performance with VMAT was noted at <0.8583, while VMAT+IMRT and IMRT+VMAT recorded thresholds of <0.9685 and <0.9283, respectively.

Tables 4 and 5 demonstrate thorough examination of RF and integral doses across the VMAT, VMAT+IMRT and IMRT+VMAT techniques has yielded intricate insights regarding cardiac and pulmonary structures. For cardiac assessment, the mean tolerance dose was established at 26 Gy, with pericarditis as the endpoint. The RF values ranged from 0.06 ± 0.040 to 0.10 ± 0.591, while the correlation coefficients between the integrated score and RF fluctuated between 0.29 and 0.53. In the case of pulmonary evaluation, the mean tolerance dose was set at 20 Gy, with radiation pneumonitis as the endpoint. Here, the RF values were notably higher, ranging from 0.49 ± 0.072 to 0.57 ± 0.095, and the correlations between the integrated score and RF varied from 0.55 to 0.75. The assessment of integral doses indicated statistically significant differences among the techniques employed. While no major differences were noted for the PTV, the analysis of OAR revealed significant variations. The VMAT+IMRT group recorded the highest integral dose for OAR, with distinct variations observed for specific structures. The left lung exhibited significantly lower integral doses when utilising the VMAT technique, whereas the heart showed increased integral doses with the VMAT+IMRT and IMRT+VMAT techniques compared to the VMAT technique. Additionally, the integral doses for the right lung and contralateral breast displayed significant differences, with the VMAT technique resulting in lower doses for the right lung and the IMRT+VMAT technique yielding the lowest integral dose for the contralateral breast. These results highlight the intricate dosimetric properties of various radiotherapy techniques and their potential ramifications for treatment planning.




Figure 4. (a). Correlation coefficients between individual and integrated scores in the left lung. (b) Correlation coefficients between individual and integrated scores in the heart. (c) Correlation coefficients between individual and integrated scores in the OARs.

Discussion

A thorough examination of three distinct radiotherapy planning approaches for left-sided breast cancer VMAT, VMAT+IMRT and IMRT+VMAT has yielded several significant insights. Figure 3 presents the correlation coefficients between individual and integrated scores across various dosimetric parameters for the PTV, highlighting particularly strong positive correlations in the Gradient Index (GI) for all three methods (VMAT_IS, IMRT+VMAT_IS and VMAT+IMRT_IS), with correlation coefficients ranging from approximately 0.65 to 0.85.

In the in-depth evaluation, VMAT exhibited superior efficacy, with 43.9% of plans attaining an 'Excellent' rating for PTV coverage, outperforming both IMRT+VMAT (51.2%) and VMAT+IMRT (53.7%). This assessment employed a stringent plan quality classification system based on mean (μ) and standard deviation (σ), categorising plans as 'Excellent' ($< \mu - \sigma$), 'Good' ($\mu - \sigma$ to μ), 'Average' (μ to $\mu + \sigma$) or 'Poor' ($> \mu + \sigma$). The correlation analysis depicted in Figure 3 also uncovers intriguing trends in additional parameters, such as COI, UI and HI, where moderate positive correlations were noted, while CI exhibited negative correlations for certain techniques. A particularly noteworthy observation was VMAT's consistent performance, as it was the only method that did not yield any 'Poor' PTV plans, whereas VMAT+IMRT had a 2.4% incidence of such plans. In terms of organ-at-risk (OAR) sparing, all methods demonstrated relatively low success rates, with only 14.6% achieving 'Excellent' status.

Nevertheless, the majority of plans were classified as 'Good,' with VMAT leading at 48.8%, followed by IMRT+VMAT at 43.9% and VMAT+IMRT at 41.5%. The BODY D2cc parameter in Figure 3 exhibited varying correlation levels across the techniques, with V_IS showing a moderate positive correlation, while IMRT+VMAT_IS and VMAT+IMRT_IS displayed lower correlation values. VMAT's superior performance was further substantiated by its lower thresholds for 'Excellent' classification (PTV: < 1.0473 , OAR: < 0.8583). These results are consistent with prior research conducted by Virén *et al.*²⁴ observed improved PTV coverage with VMAT. These findings indicate that VMAT could provide an ideal equilibrium between PTV coverage and the protection of OARs.

A comprehensive evaluation of OAR protection highlighted the unique benefits of VMAT in preserving lung tissue, evidenced by a significantly reduced average lung dose of 12.69 Gy and a V20Gy of 24.90%. Although VMAT exhibited favorable V35Gy values at 10.5%, its V5Gy measurement of 59.81% approached critical limits. Notably, the hybrid technique's V5Gy of 56.69% may present a slightly safer option for patients at risk of radiation pneumonitis, as indicated by prior studies from Marks *et al.*²⁵ and Yoo *et al.*²⁶ In summary, VMAT offers considerable benefits in limiting high-dose exposure to the lungs while carefully addressing the potential for radiation-induced complications. Regarding cardiac protection, VMAT outperformed other methods, achieving a mean heart dose of 5.14 Gy and a V5Gy of 22.16%, which may contribute to a decreased risk of coronary events, as indicated by

Darby et al.'s³ research showing a 7.4% increase in risk per Gray of mean heart dose. Additionally, the reduced V25Gy and V35Gy values associated with demonstrate in Table 2 could further mitigate long-term cardiovascular risks (Taylor et al.)²⁷ as demonstrated in Table 2.

The correlation analysis illustrated in Figure 3, along with the extensive OAR dosimetric parameters presented in Figure 4, offers valuable insights into the effectiveness of the treatment. The findings from the correlation analysis in Figure 4 reveal several significant observations across various anatomical structures: Figure 4(a) indicates strong positive correlations for dosimetric parameters of the left lung, particularly V35Gy, Dmean and V20Gy, with VMAT+IMRT demonstrating a notably high responsiveness to changes in Dmean (0.77) and V20Gy (0.71). Notably, VMAT exhibited a negative correlation for V5Gy (-0.33), suggesting that low-dose lung volumes are less significant in its planning. The analysis of heart parameters in Figure 4(b) showed that the IMRT+VMAT technique had the strongest correlations for Dmean (0.65) and V35Gy (0.60), while negative correlations for V5Gy were noted across all techniques (VMAT: -0.40, IMRT+VMAT: -0.27), indicating a reduced significance of low-dose heart volumes. Figure 4(c) emphasises VMAT's moderate sensitivity to doses affecting the contralateral breast (0.48) and spinal cord (0.38), as well as the highest sensitivity to the right lung dose (0.36), while correlations for the oesophagus and thyroid were notably weak. Importantly, VMAT exhibited superior plan consistency, reflected in the lowest overall integrated score of 1.0931 and the smallest standard deviation of 0.2645. Regarding risk assessment, VMAT demonstrated lower risk levels for both cardiac (0.06 ± 0.040) and pulmonary (0.49 ± 0.072) complications when compared to hybrid techniques.

The analysis of correlation between integrated scores and RF indicated moderate correlations for heart RF (VMAT: 0.34, VMAT+IMRT: 0.29 and IMRT+VMAT: 0.53) and stronger correlations for lung RF (VMAT: 0.67, VMAT+IMRT: 0.75 and IMRT+VMAT: 0.55). It is crucial to highlight that VMAT produced higher integral doses for the right lung and the contralateral breast in comparison to hybrid techniques, as demonstrated in Table 5. This underscores the necessity for personalised treatment planning, especially for patients with pre-existing conditions or those at elevated risk for contralateral breast cancer. These extensive findings support the overall advantages of VMAT while recognising specific circumstances where hybrid methods may be more suitable.

Conclusion

The study results indicate that VMAT is the most advantageous radiotherapy method for left-sided breast cancer accompanied by regional nodal irradiation. This technique achieved optimal dosimetric performance, evidenced by the lowest gradient index (2.95) while consistently maintaining conformity and homogeneity indices. VMAT's enhanced OAR sparing capabilities resulted in reduced mean doses to critical structures, particularly the heart and left lung, leading to a higher proportion of Good and Excellent treatment plans compared to hybrid approaches.

While the technique introduces marginally increased low-dose exposure to contralateral structures warranting patient-specific evaluation, its overall dosimetric advantages establish VMAT as the preferred treatment modality. The strong positive correlation between Gradient Index and integrated scores, especially in hybrid techniques, further validates VMAT's effectiveness. Future

research should focus on evaluating long-term clinical outcomes to validate these dosimetric benefits and refine patient selection criteria, ultimately optimising therapeutic outcomes in breast cancer radiation therapy.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: Cancer J Clin* 2021; 71 (3): 209–249. <https://doi.org/10.3322/caac.21660>
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *The Lancet* 2014; 383 (9935): 2127–2135. [https://doi.org/10.1016/S0140-6736\(14\)60488-8](https://doi.org/10.1016/S0140-6736(14)60488-8)
3. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013; 368 (11): 987–998. <https://doi.org/10.1056/NEJMoa1209825>
4. Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. *Radiother Oncol* 2015; 114 (1): 56–65. <https://doi.org/10.1016/j.radonc.2014.10.004>
5. Moorthy S, Sakr H, Hasan S. Dosimetric study of SIB-IMRT versus SIB-3DCRT for breast cancer with breath-hold gated technique. *Int J Cancer Ther Oncol* 2013; 1 (1): 010110. <https://doi.org/10.14319/ijcto.0101.10>
6. Hall EJ, Wu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys* 2003; 56 (1): 83–88. [https://doi.org/10.1016/S0360-3016\(03\)00073-7](https://doi.org/10.1016/S0360-3016(03)00073-7)
7. Donovan EM, James H, Bonora M, Yarnold JR, Evans PM. Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer. *Med Phys* 2012; 39 (10): 5814–5824. <https://doi.org/10.1118/1.4748332>
8. Lin JF, Yeh DC, Yeh HL, Chang CF, Lin JC. Dosimetric comparison of hybrid volumetric-modulated arc therapy, volumetric-modulated arc therapy, and intensity-modulated radiation therapy for left-sided early breast cancer. *Med Dosim* 2015; 40 (3): 262–267. <https://doi.org/10.1016/j.meddos.2015.05.003>
9. Akbas U, Koksall C, Kesen ND, Ozkaya K, Bilge H, Altun M. Nasopharyngeal carcinoma radiotherapy with hybrid technique. *Med Dosim* 2019; 44 (3): 251–257. <https://doi.org/10.1016/j.meddos.2018.09.003>
10. Wagner TH, Bova FJ, Friedman WA, Buatti JM, Bouchet LG, Meeks SL. A simple and reliable index for scoring rival stereotactic radiosurgery plans. *Int J Radiat Oncol Biol Phys* 2003; 57 (4): 1141–1149. [https://doi.org/10.1016/S0360-3016\(03\)01563-3](https://doi.org/10.1016/S0360-3016(03)01563-3)
11. Hernandez V, Hansen, CR, Widesott L, Bäck A, Canters R, Fusella M, Götstedt J, Jurado-Bruggeman D, Mukumoto N, Kaplan LP, Koniarová I, Piotrowski T, Placidi L, Vaniqui A, Jornet N. What is plan quality in radiotherapy? The importance of evaluating dose metrics, complexity, and robustness of treatment plans. *Radiother Oncol* 2020; 153, 26–33. <https://doi.org/10.1016/j.radonc.2020.09.038>
12. Akpati H, Kim C, Kim B, Park T, Meek A. Unified dosimetry index (UDI): a figure of merit for ranking treatment plans. *J Appl Clin Med Phys* 2008; 9 (3): 99–108. <https://doi.org/10.1120/jacmp.v9i3.2803>
13. Mambretti M, Romanò C, Marvaso G, Comi S, Cambria R, Ciardo D, Emiro F, Fodor C, Zerini D, Riva G, Petralia G, De Cobelli O, Orecchia R, Cattani F, Jereczek-Fossa BA. A global unified dosimetry index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer. *Radiother Oncol* 2018; 128 (2): 315–320. <https://doi.org/10.1016/j.radonc.2018.06.002>
14. Leung LH, Kan MW, Cheng AC, et al.. A new dose-volume-based Plan Quality Index for IMRT plan comparison. *Radiother Oncol* 2007; 85 (3): 407–417. <https://doi.org/10.1016/j.radonc.2007.10.018>

15. Ruan D, Shao W, Demarco J, et al.. Evolving treatment plan quality criteria from institution-specific experience. *Med Phys* 2012; 39 (5): 2708–2712. <https://doi.org/10.1118/1.4704497>
16. Song T, Staub D, Chen M. Patient-specific dosimetric endpoints based treatment plan quality control in radiotherapy. *Phys Med Biol* 2015; 60 (21): 8213–8227. <https://doi.org/10.1088/0031-9155/60/21/8213>
17. Alfonso JCL, Herrero MA, Núñez L. A dose-volume histogram based decision-support system for dosimetric comparison of radiotherapy treatment plans. *Radiat Oncol* 2015; 10: 263. <https://doi.org/10.1186/s13014-015-0569-3>
18. Balaji K, Ramasubramanian V. Integrated scoring approach to assess radiotherapy plan quality for breast cancer treatment. *Rep Pract Oncol Radiother* 2022; 27 (4): 707–716. <https://doi.org/10.5603/RPOR.a2022.0083>
19. Ansari S, Zope MK, Yadav N. A new method for risk factor assessment of organs at risk including conformity index in radiotherapy treatment plan. *J Radiother Pract* 2021; 20 (2): 144–152. <https://doi.org/10.1017/S1460396920000205>
20. Radiation Therapy Oncology Group (RTOG). Contouring Atlases: Breast Cancer Atlas. Available at: <https://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.asp>. Accessed Apr 8, 2018.
21. Patil D, Zope M, Madhawi R, Raj S, Kishor K, Devi S, Singh R, Singh D. Physical and radiobiological dosimetric comparison of volumetric arc treatment plans with or without flattening filter in synchronous bilateral breast cancer. *Turk J Oncol* 2024; 39 (4): 411–422.
22. Shi C, Peñagaricano J, Papanikolaou N. Comparison of IMRT treatment plans between linac and helical tomotherapy based on integral dose and inhomogeneity index. *Med Dosim* 2008; 33: 215–221.
23. Zope MK, Patil DB, Saroj DK. Assessment of organ-at-risk sparing in esophageal cancer: a comparative dosimetric evaluation of hybrid, noncoplanar, and coplanar rapidarc plans. *J Med Phys* 2024; 49 (3): 419–426.
24. Virén T, Heikkilä J, Myllyoja K, Koskela K, Lahtinen T, Seppälä J. Tangential volumetric modulated arc therapy technique for left-sided breast cancer radiotherapy. *Radiat Oncol* 2015; 10: 79. <https://doi.org/10.1186/s13014-015-0392-x>
25. Marks LB, Yorke ED, Jackson A. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010; 76 (3): S70–S76. <https://doi.org/10.1016/j.ijrobp.2009.06.091>
26. Yoo S, Goodman C, Cress R. Is the risk of radiation pneumonitis different in patients treated with conventional versus hypofractionated radiation therapy for breast cancer? *Radiother Oncol* 2012; 104 (2): 229–234. <https://doi.org/10.1016/j.radonc.2012.08.015>
27. Taylor CW, Kirby AM. Cardiac side-effects from breast cancer radiotherapy. *Clin Oncol* 2017; 27 (11): 621–629. <https://doi.org/10.1016/j.clon.2015.06.007>